

## Kicking the Tires 2: Life Sciences and FDA Diligence

NOVEMBER 18, 2020

In the second episode in our Health Care & Life Sciences M&A Webinar Series, we discussed major areas of regulatory risk in acquiring businesses in the life sciences industry and/or regulated by food and drug law. Discussion topics included:

- FDA pharmaceutical approvals
- FDA device approvals
- FDA enforcement/recall/notice letter activity
- Fraud and abuse issues
- Post-acquisition integration issues
- Government reimbursement and policy issues
- Third party issues
- Supply chain issues

Listen to the webinar [here](#). Listen to a recording from the first webinar “Kicking the Tires 1: Key Regulatory Diligence Considerations” [here](#).

View the full series schedule [here](#).

1 Min Read

---

### Related Locations

New York

Washington, DC

## Related Capabilities

Mergers & Acquisitions

Transactions

Health Care

## Related Regions

North America

## Related Professionals

---



T. Reed Stephens